Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $2.99
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 22, 26 | HC Wainwright & Co. |
Daily · Wilder smoothing
| maintain |
| Buy |
| Buy |
| Apr 8, 26 | D. Boral Capital | maintain | Buy | Buy |
| Mar 31, 26 | D. Boral Capital | maintain | Buy | Buy |
| Feb 4, 26 | D. Boral Capital | maintain | Buy | Buy |
| Dec 12, 25 | D. Boral Capital | maintain | Buy | Buy |
| Oct 7, 25 | D. Boral Capital | maintain | Buy | Buy |
| Sep 22, 25 | D. Boral Capital | maintain | Buy | Buy |
| Sep 11, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 9, 25 | D. Boral Capital | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 57.13 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 43.03 | Oscillator | Neutral |
| Williams %R (14) | -27.78 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.05 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 20.51 (+DI 27.8 / -DI 15.1) | Trend | Buy |
| EMA 20 | 2.81 | MA | Strong Buy |
| SMA 20 | 2.82 | MA | Strong Buy |
| EMA 50 | 2.92 | MA | Buy |
| SMA 50 | 3.00 | MA | Sell |
| SMA 200 | 2.97 | MA | Buy |
FY2019 · 10-K disclosure
FY2012 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | ANIX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -9.8x | -11.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -9.4x | EPS est. -0.32 | In line |
| Price / Book | 7.1x | 5.7x | Elevated |
| Price / Sales | — | 150.1x | Discount |
| EV / EBITDA | -9.7x | -10.2x | In line |
| Return on equity | -70.4% | — | Weak |
| Gross margin | 0.0% | 9.6% | Below hist. |
| Debt / Equity | 0.01 | 0.01 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 7.94 | Safe zone |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 22, 2026 | 2026-10-22 17:44:15 | View |
| 4 | Sep 30, 2026 | 2026-09-30 10:25:37 | View |
| 4 | Sep 28, 2026 | 2026-09-28 08:45:19 | View |
| 4 | Sep 28, 2026 | 2026-09-28 08:30:18 | View |
| 4 | Sep 25, 2026 | 2026-09-25 08:39:59 | View |
| 4 | Sep 14, 2026 | 2026-09-14 09:45:02 | View |
| 4 | Sep 14, 2026 | 2026-09-14 09:15:10 | View |
| 4 | Sep 11, 2026 | 2026-09-11 08:00:26 | View |
| 10-Q | Sep 9, 2026 | 2026-09-09 16:15:36 | View |
| 4 | Aug 3, 2026 | 2026-08-03 08:45:18 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 22, 26 | Kumar Amit | director, officer: Chief Executive Officer | P-Purchase | 8,000 @ $2.72 | $21.76K |
| Sep 30, 26 | Catelani Michael | officer: President, COO, & CFO | P-Purchase | 5,500 @ $2.84 | $15.62K |
| Sep 24, 26 | Kumar Amit | director, officer: Chief Executive Officer | P-Purchase | 7,000 @ $2.78 | $19.46K |
| Sep 24, 26 | Baskies Arnold M | director | P-Purchase | 5,000 @ $2.76 | $13.80K |
| Sep 23, 26 | Titterton Lewis H Jr | director | P-Purchase | 49,036 @ $2.69 | $131.9K |
| Sep 10, 26 | Kumar Amit | director, officer: Chief Executive Officer | P-Purchase | 3,000 @ $2.75 | $8.25K |
| Sep 10, 26 | Titterton Lewis H Jr | director | P-Purchase | 10,000 @ $2.73 | $27.30K |
| Sep 10, 26 | Kumar Amit | director, officer: Chief Executive Officer | P-Purchase | 5,000 @ $2.76 | $13.80K |
Stock news · updated daily
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference.
First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) Director Arnold Baskies purchased 5,000 shares of the firm's stock in a transaction on Thursday, September 24th. The shares were acquired at an average price of $2.76 per share, with a total value of $13,800.00. Following the purchase, the director directly owned 140,572 shares in the company,
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) CEO Amit Kumar acquired 7,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, September 24th. The shares were bought at an average price of $2.78 per share, with a total value of $19,460.00. Following the transaction, the chief executive officer directly owned 672,000
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., Sept. 21, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic.
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D.
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 9, 2026 | -0.08 | -0.08 | Beat 3.3% | — |
| Jun 10, 2026 | -0.10 | -0.07 | Beat 30.0% | — |
| Mar 9, 2026 | -0.09 | -0.08 | Beat 11.1% | — |
| Jan 12, 2026 | -0.09 | -0.09 | Miss -2.3% | — |
| Sep 10, 2025 | -0.10 | -0.07 | Beat 30.0% | — |
| May 28, 2025 | -0.10 | -0.09 | Beat 10.0% | — |